Recursion Pharmaceuticals (NASDAQ: RXRX), a small-cap biotech company, has one claim to fame: It currently owns the largest ...

Here is the AI research roadmap for 2026: how agents that learn, self-correct, and simulate the real world will redefine ...

I played these 25 cards the most and built so many decks around them — or at least dreamed how they might function in the ...

Broadcom enters 2026 at an inflection point, with strong tailwinds from its ASIC and Networking segments. Read why AVGO stock ...

The year 2025 marked a major leap for AI in health care, with breakthroughs in drug discovery, diagnostics, genomics and ...

Takeda regains a majority of XOMA Royalty’s royalty interest in mezagitamab (TAK-079) –– XOMA Royalty will be entitled to payments based on a ...

Former Google CEO Eric Schmidt believes AI's rapid advancement, already handling 10-20% of programming tasks, signals the end ...

One of the key learning outcomes of university education in general, and liberal arts programmes,  in particular, is that ...

Fruchter, G. (2026) Opportunism in Supply Chain Recommendations: A Dynamic Optimization Approach. Modern Economy, 17, 26-38.

Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...